Antiviral therapy of HCV-cirrhosis: case of sequential treatment and review of literature

Противовирусная терапия HCV-цирроза: случай последовательного лечения и обзор литературы
Kakharman Yesmembetov 1 2, Aiymkul Ashimkhanova 3, Kulpash Kaliaskarova 1 2
More Detail
1 Department of Hepatology, Clinic of Hepatology, Gastroenterology and Transplantation, Astana, Republic of Kazakhstan
2 Department of Hepatology, Republican Diagnostic Center, University Medical Center, Astana, Republic of Kazakhstan
3 School of Medicine, Nazarbayev University, Astana, Republic of Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 47, pp. 41-43. https://doi.org/10.23950/1812-2892-JCMK-00302
OPEN ACCESS 2895 Views 1970 Downloads
Download Full Text (PDF)

ABSTRACT

This clinical case demonstrates a history of 40-year old male with decompensated liver cirrhosis due to hepatitis C (genotype 1). The patient was started on direct acting antiviral therapy with sofosbuvir and simeprevir in order to decrease rate of disease progression. Treatment was associated with marked improvement of patient’s condition and resolving of ascites. Negative viremia was achieved after week 8 of antiviral therapy and the treatment was completed on week 12. However, evaluation on post-treatment week 12 has demonstrated recurrence of hepatitis C virus with sharp increase of liver transaminases of higher than 20 times upper limit normal. Second round of direct acting antiviral agents including ombitasvir, paritaprevir, dasabuvir and ritonavir was started. Negative viremia was achieved on week 4 with consequent demonstration of end of treatment and sustained virological response at 12 weeks post-treatment. This clinical case demonstrates need for personalized approach to antiviral therapy in each patient with modification of the treatment regimen by prolongation or implementing additional antiviral agent, if needed.

CITATION

Yesmembetov K, Ashimkhanova A, Kaliaskarova K. Antiviral therapy of HCV-cirrhosis: case of sequential treatment and review of literature. Journal of Clinical Medicine of Kazakhstan. 2018;1(47):41-3. https://doi.org/10.23950/1812-2892-JCMK-00302

REFERENCES

  • Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol. 2007; 46(2):206-212.
  • Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009; 50(4):719-728.
  • Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010; 32(13):2117-2138.
  • Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014; 60(1):37-45.
  • Gamal N, Vitale G, Andreone P. ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. Expert Rev Anti Infect Ther. 2015; 13(3):295-304.
  • Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010; 32(13): 2117-2138.
  • Pawlotsky J.M, Aghemo A, Dusheiko G, Forns X, Puoti M, Sarrazin C. EASL recommendations on treatment of hepatitis C. 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/mobile/index.html#p=1.
  • Jacobson I, Ghalib RH, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski M. et al. SVR results of once-daily regimen of simeprevir (TMC435) and sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null-responder patients: the COSMOS study. Hepatology. 2013; 58(1):1379A.
  • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3):211-221.
  • Bourliere M, Bronowski JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P. et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology. 2014; 60:1271A.
  • Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-1982.